Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ferring Pharmaceuticals, Inc. and Merck & Co., Inc.

Community Practice Connections™: Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward

Release Date: July 31, 2019
Expiration Date: July 31, 2020
Media: Internet - based

Activity Overview

Now, even while clinicians are sorting through data from clinical studies of single-agent immunotherapy for advanced/metastatic urothelial cancer (UC), the field is poised to pivot again as a multitude of ongoing clinical studies are evaluating single-agent and combination immunotherapy (IO) strategies across all stages of bladder cancer. Additionally, novel agents are being studied to address the unmet needs of patients with UC that is refractory to immune checkpoint inhibitor therapy. Use of these agents across multiple lines of therapy for advanced UC and the potential expansion of their use to early-stage disease makes it imperative that urologists, as the primary care providers for patients with early-stage disease and the gatekeepers for referral to other specialists, understand both new data and best practices related to the use of IO, including proactively monitoring, mitigating, and managing immune-related adverse events. This interactive, online activity is based on a live symposium held adjunct to the 2019 annual urology meeting in Chicago. Through a series of brief video interviews, the multidisciplinary faculty—comprising renowned experts in urology, medical oncology, and IO—review practice-changing data and its impact on patient care, discuss “real-world” clinical cases, and share forward-looking perspectives on the bladder cancer treatment horizon.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Ferring Pharmaceuticals, Inc. and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers involved in the treatment of patients with bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with bladder cancers are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify the rationale for using immunotherapy (IO)-based approaches to treat bladder cancer
  • Analyze key data from clinical trials of IO and other emerging agents for bladder cancer
  • Consider practice-changing evidence from clinical trials of IO, cytotoxic agents, and targeted therapies during multidisciplinary, team-based care planning for patients with bladder cancer
  • Outline immune-related adverse events and best practices for their mitigation and management

Faculty, Staff, and Planners’ Disclosures


Daniel P. Petrylak
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics; Consultant: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen; Shareholder: Bellicum, Tyme.


Bernard H. Bochner
Bernard H. Bochner, MD
Attending Surgeon, Urology Service
Sir Murray Brennan Chair in Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: National Institutes of Health; Consultant: Genentech, Olympus.

Leonard G. Gomella
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director for Clinical Affairs, Jefferson Kimmel Cancer Center
Clinical Director, Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA

Disclosures: Consultant: Astellas, Bayer, Merck, Strand; Other: NCI-NRG.

Maha Hussain
Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures: Grant/Research Support: AstraZeneca, Pfizer, Bayer, Genentech; Consultant: Pfizer, AstraZeneca, Bayer; Other: Sanofi, Genzyme, Genentech.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By